T cell imaging in kidney transplantation (TIK)

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522490-11-00

Enrollment

Registered

2026-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal allograft rejection

Brief summary

The [89Zr]-Df-Crefmirlimab PET signal in kidneys (native/graft), lymph nodes (cervical, hilair, mediastinal), spleen, liver and bone marrow in patients with and without rejection or T cell depleting therapy.

Detailed description

In addition to the [89Zr]Df-Crefmirlimab PET/CT, we will also quantify various immune cell subsets, such as CD8+ T cells, in blood by flow cytometry.

Interventions

DRUGZr89

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The [89Zr]-Df-Crefmirlimab PET signal in kidneys (native/graft), lymph nodes (cervical, hilair, mediastinal), spleen, liver and bone marrow in patients with and without rejection or T cell depleting therapy.	—

Secondary

Measure	Time frame
In addition to the [89Zr]Df-Crefmirlimab PET/CT, we will also quantify various immune cell subsets, such as CD8+ T cells, in blood by flow cytometry.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 5, 2026